Garry E Menzel has sold stock and made no open-market buys since Dec 2022

Dr. Garry E. Menzel is a corporate insider and Non‑Executive Director of Adaptimmune Therapeutics plc (ticker: ADAP), where he has served on the Board since June 2023 following Adaptimmune’s merger with TCR² Therapeutics.( In his role at Adaptimmune, he contributes more than 25 years of experience building healthcare businesses, with responsibilities that have spanned drug development, manufacturing, commercialization, financing, and M&A.( He previously served as President and Chief Executive Officer of TCR² Therapeutics, leading the oncology company from concept to clinical success with novel immunotherapies for solid tumors and through its strategic merger with Adaptimmune.(

Menzel’s career includes senior operating roles as Chief Financial Officer of DaVita Healthcare, a Fortune 500 kidney dialysis and primary care physician company, and Chief Operating Officer of Regulus Therapeutics, a microRNA therapy company.( He also held global leadership positions in biotechnology investment banking at Goldman Sachs and Credit Suisse, advising on more than $100 billion in strategic transactions.( In addition to his Adaptimmune directorship, he has been a founding board member of Black Diamond Therapeutics and a director of Stoke Therapeutics and other life sciences companies.( Menzel earned his Ph.D. from the University of Cambridge for research on oncogene regulation in immune cells and holds an M.B.A. from the Stanford Graduate School of Business, as well as a B.Sc. (Hons) in Biochemistry from Imperial College.(

Written by Perplexity from public sources.